Evidence map›Paper›PMID 27494869›Full record

ArticleOncotarget2016

miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression.

Ya-Ping Ye, Ping Wu, Chun-Cai Gu, Dan-Ling Deng, Hong-Li Jiao, Ting-Ting Li, Shu-Yang Wang, Yong-Xia Wang, Zhi-Yuan Xiao, Wen-Ting Wei and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. International journal of general medicine · 2023
    Article
  8. Article
  9. Article
  10. Interplay between K-RAS and miRNAs.Trends in cancer · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Ya-Ping YeDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Ping WuDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Chun-Cai GuDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Dan-Ling DengDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Hong-Li JiaoDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Ting-Ting LiDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Shu-Yang WangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yong-Xia WangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zhi-Yuan XiaoDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Wen-Ting WeiDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yan-Ru ChenDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jun-Feng QiuDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Run-Wei YangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jie LinDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Li LiangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Wen-Ting LiaoDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yan-Qing DingDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Nanfang Hospital · CNKey Laboratory of Guangdong Province · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development and progression of CRC are regarded as a complicated network and progressive event including genetic and/or epigenetic alterations. Recent researches revealed that MicroRNAs are biomarkers and regulators of CRC progression. Analyses of published microarray datasets revealed that miR-450b-5p was highly up-regulated in CRC tissues. In addition, high expression of miR-450b-5p was significantly associated with KRAS mutation. However, the role of miR-450b-5p in the progression of CRC remains unknown. Here, we sought to validate the expression of miR-450b-5p in CRC tissues and investigate the role and underlying mechanism of miR-450b-5p in the progression of CRC. The results revealed that miR-450b-5p was up-regulated in CRC tissues, high expression level of miR-450b-5p was positively associated with poor differentiation, advanced TNM classification and poor prognosis. Moreover, miR-450b-5p was especially high in KRAS-mutated cell lines and could be up-regulated by KRAS/AP-1 signaling. Functional validation revealed that overexpression of miR-450b-5p promoted cell proliferation and tumor growth while inhibited apoptosis of CRC cells. Furthermore, we demonstrated that miR-450b-5p directly bound the 3'-UTRs of SFRP2 and SIAH1, and activated Wnt/β-Catenin signaling. In conclusion, miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. Collectively, our work helped to understand the precise role of miR-450b-5p in the progression of CRC, and might promote the development of new therapeutic strategies against CRC.

Indexed as

3' Untranslated RegionsAnimalsApoptosisBiomarkers, TumorCell DifferentiationCell Line, TumorCell ProliferationColorectal NeoplasmsDisease ProgressionEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGenes, rasHCT116 CellsHumansMembrane Proteins3' Untranslated RegionsBiomarkers, TumorMembrane ProteinsMicroRNAsMIRN450 microRNA, humanNuclear Proteinsras ProteinsSecreted Frizzled-Related ProteinsSeven in Absentia ProteinsSFRP2 protein, humanUbiquitin-Protein Ligasescolorectal cancerKRASmiR-450b-5pprogressionWnt/β-Catenin pathway

Identifiers

PMID27494869
PMCPMC5308653
OpenAlexW2502940265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.